News

The associate professor of neurology at Johns Hopkins Medicine previewed a 2025 AUPN panel exploring AI’s clinical, research, and educational applications, along with the ethical considerations shaping its responsible adoption. [WATCH TIME: 2 minutes]

Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer disease field presented at the 2025 Alzheimer’s Association International Conference.

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025.

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.

Catch up on any of the neurology news headlines you may have missed over the course of July 2025, compiled all into 1 place by the NeurologyLive® team.

New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a marker of treatment response in these autoimmune diseases.

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer disease, urging further research for validation.

Here's some of what is coming soon to NeurologyLive® this week.

In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on orexin receptor agonists.

Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.

New findings reveal ACP-204 shows no significant QT interval prolongation in healthy adults, supporting its safety for Alzheimer disease psychosis treatment.

Neurology News Network. for the week ending August 9, 2025. [WATCH TIME: 4 minutes]

Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 8, 2025.

The director of pediatric epilepsy at NYU Langone Medical Center shared expert insights on improving transitions from pediatric to adult epilepsy care. [WATCH TIME: 3 minutes]

The corporate vice president of medical information and research at Theranica discussed long-term findings presented at AHS 2025 covering the company’s Nerivio remote electrical neuromodulation device for patients with migraine. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alexa Dessy, MD. [LISTEN TIME: 17 minutes]

Two experts from Cerevance discussed data from the company’s posters recently presented at AAIC 2025, which highlighted potential therapeutic targets for Alzheimer disease. [WATCH TIME: 5 minutes]

Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and depression.

Donanemab has received a positive opinion from the European Medicines Agency’s CHMP for the treatment of early symptomatic Alzheimer disease, bringing Eli Lilly’s anti-amyloid therapy one step closer to approval in the European Union.

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC-841, a novel anti-SIGLEC10 antibody targeting amyloid and tau in Alzheimer disease.

Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.

At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]